Oramed COO & CBO Joshua Hexter sells $135,330 in shares

Oramed Pharmaceuticals Inc.'s COO and CBO, Joshua Hexter, sold 30,000 shares of the company's stock on October 1, 2026. The transactions were carried out under a pre-approved trading plan, lasting from March 30, 2026. The sale amounted to $135,330, with each share priced between $4.440 and $4.650, averaging $4.511. This comes after Oramed stock's strong performance over the past year, delivering a 92% return and a 31% increase over the last six months.

Following the sales, Mr. Hexter personally owns 1,328,130 shares of Oramed Pharmaceuticals Inc. stock. The stock appears undervalued, with a 5.6% dividend yield. Investors can obtain additional financial insights through InvestingPro's ProTips on their platform.

In other news, Oramed Pharmaceuticals held its annual meeting for stockholders on the same day. Shareholders approved six proposals, re-electing six directors to serve until the next annual meeting. The vote tallies for each director were between 11,567,510 and 13,702,335 in favor, while opposition ranged from 3,729,485 to 5,859,953. This re-election indicates shareholder confidence in the current leadership team.